Cargando…
Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19
Venous thromboembolism (VTE) has emerged as an important issue in patients with COVID-19. The purpose of this study is to identify the incidence of VTE and mortality in COVID-19 patients initially presenting to a large health system. Our retrospective study included adult patients (excluding patient...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932762/ https://www.ncbi.nlm.nih.gov/pubmed/33665766 http://dx.doi.org/10.1007/s11239-021-02413-7 |
_version_ | 1783660480204636160 |
---|---|
author | Giannis, Dimitrios Barish, Matthew A. Goldin, Mark Cohen, Stuart L. Kohn, Nina Gianos, Eugenia Chatterjee, Saurav Lesser, Martin Coppa, Kevin Hirsch, Jamie S. McGinn, Thomas Spyropoulos, Alex C. |
author_facet | Giannis, Dimitrios Barish, Matthew A. Goldin, Mark Cohen, Stuart L. Kohn, Nina Gianos, Eugenia Chatterjee, Saurav Lesser, Martin Coppa, Kevin Hirsch, Jamie S. McGinn, Thomas Spyropoulos, Alex C. |
author_sort | Giannis, Dimitrios |
collection | PubMed |
description | Venous thromboembolism (VTE) has emerged as an important issue in patients with COVID-19. The purpose of this study is to identify the incidence of VTE and mortality in COVID-19 patients initially presenting to a large health system. Our retrospective study included adult patients (excluding patients presenting with obstetric/gynecologic conditions) across a multihospital health system in the New York Metropolitan Region from March 1-April 27, 2020. VTE and mortality rates within 8 h of assessment were described. In 10,871 adults with COVID-19, 118 patients (1.09%) were diagnosed with symptomatic VTE (101 pulmonary embolism, 17 deep vein thrombosis events) and 28 patients (0.26%) died during initial assessment. Among these 146 patients, 64.4% were males, 56.8% were 60 years or older, 15.1% had a BMI > 35, and 11.6% were admitted to the intensive care unit. Comorbidities included hypertension (46.6%), diabetes (24.7%), hyperlipidemia (14.4%), chronic lung disease (12.3%), coronary artery disease (11.0%), and prior VTE (7.5%). Key medications included corticosteroids (22.6%), statins (21.2%), antiplatelets (20.6%), and anticoagulants (20.6%). Highest D-Dimer was greater than six times the upper limit of normal in 51.4%. Statin and antiplatelet use were associated with decreased VTE or mortality (each p < 0.01). In COVID-19 patients who initially presented to a large multihospital health system, the overall symptomatic VTE and mortality rate was over 1.0%. Statin and antiplatelet use were associated with decreased VTE or mortality. The potential benefits of antithrombotics in high risk COVID-19 patients during the pre-hospitalization period deserves study. |
format | Online Article Text |
id | pubmed-7932762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-79327622021-03-05 Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19 Giannis, Dimitrios Barish, Matthew A. Goldin, Mark Cohen, Stuart L. Kohn, Nina Gianos, Eugenia Chatterjee, Saurav Lesser, Martin Coppa, Kevin Hirsch, Jamie S. McGinn, Thomas Spyropoulos, Alex C. J Thromb Thrombolysis Article Venous thromboembolism (VTE) has emerged as an important issue in patients with COVID-19. The purpose of this study is to identify the incidence of VTE and mortality in COVID-19 patients initially presenting to a large health system. Our retrospective study included adult patients (excluding patients presenting with obstetric/gynecologic conditions) across a multihospital health system in the New York Metropolitan Region from March 1-April 27, 2020. VTE and mortality rates within 8 h of assessment were described. In 10,871 adults with COVID-19, 118 patients (1.09%) were diagnosed with symptomatic VTE (101 pulmonary embolism, 17 deep vein thrombosis events) and 28 patients (0.26%) died during initial assessment. Among these 146 patients, 64.4% were males, 56.8% were 60 years or older, 15.1% had a BMI > 35, and 11.6% were admitted to the intensive care unit. Comorbidities included hypertension (46.6%), diabetes (24.7%), hyperlipidemia (14.4%), chronic lung disease (12.3%), coronary artery disease (11.0%), and prior VTE (7.5%). Key medications included corticosteroids (22.6%), statins (21.2%), antiplatelets (20.6%), and anticoagulants (20.6%). Highest D-Dimer was greater than six times the upper limit of normal in 51.4%. Statin and antiplatelet use were associated with decreased VTE or mortality (each p < 0.01). In COVID-19 patients who initially presented to a large multihospital health system, the overall symptomatic VTE and mortality rate was over 1.0%. Statin and antiplatelet use were associated with decreased VTE or mortality. The potential benefits of antithrombotics in high risk COVID-19 patients during the pre-hospitalization period deserves study. Springer US 2021-03-05 2021 /pmc/articles/PMC7932762/ /pubmed/33665766 http://dx.doi.org/10.1007/s11239-021-02413-7 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Giannis, Dimitrios Barish, Matthew A. Goldin, Mark Cohen, Stuart L. Kohn, Nina Gianos, Eugenia Chatterjee, Saurav Lesser, Martin Coppa, Kevin Hirsch, Jamie S. McGinn, Thomas Spyropoulos, Alex C. Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19 |
title | Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19 |
title_full | Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19 |
title_fullStr | Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19 |
title_full_unstemmed | Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19 |
title_short | Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19 |
title_sort | incidence of venous thromboembolism and mortality in patients with initial presentation of covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932762/ https://www.ncbi.nlm.nih.gov/pubmed/33665766 http://dx.doi.org/10.1007/s11239-021-02413-7 |
work_keys_str_mv | AT giannisdimitrios incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT barishmatthewa incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT goldinmark incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT cohenstuartl incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT kohnnina incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT gianoseugenia incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT chatterjeesaurav incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT lessermartin incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT coppakevin incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT hirschjamies incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT mcginnthomas incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT spyropoulosalexc incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 AT incidenceofvenousthromboembolismandmortalityinpatientswithinitialpresentationofcovid19 |